Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / South Africa

Research and Innovation Action · Running

OPT-bCPAP Oxygen Optimization Therapy through BCPAP for management of childhood pneumonia in general hospitals of LMICs

Coordinator
University of Cape Town Lung Institute Pty Ltd*, South Africa
Runs
1 June 2024 to 31 May 2029
Status
Running
EU funding
€4.6m
Total cost
€4.6m
Partners
7 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101145797

What the project is doing

In the project's own words, from its summary on CORDIS.

Pneumonia is a leading cause of morbidity and mortality especially among children in sub-Saharan Africa. Nigeria and Ethiopia are among the 5 countries that account for half of the under-five pneumonia deaths. Majority of the deaths from pneumonia are however preventable with early diagnosis and appropriate management. In children with pneumonia, hypoxemia is quite common and constitutes a major risk factor for death.

The WHO and other leading child health agencies urge widespread access to oxygen therapy. Bubble continuous positive airway pressure (bCPAP) is a method of delivering oxygen and positive pressure into the airways thus keeping the alveoli open for improved gas exchange. While use of bCPAP devices appears safe and effective worldwide, scaling of quality bCPAP devices in low- and middle-income countries (LMICs) has been limited.

This has prevented most children in LMICs from receiving life-saving non-invasive respiratory support which could have saved many lives. Achieving Sustainable Development Goal (SDG) 3.2 of the reduction of under-5 mortality to at least as low as 25 per 1,000 live births by 2030 will likely not be possible without access to innovative and low cost interventions devices such as bCPAP in LMICs. The aim of the OPT-bCPAP is to perform context-appropriate scale-up of bCPAP in settings of very high disease burden (Nigeria, Ethiopia and Malawi) using the the positive results and the lessons learned from clinical trials conducted in Ethiopia, Bangladesh and Ghana.

In addition to scaling up bCPAP, we will deeply explore additional factors associated with treatment failure and mortality from severe pneumonia, we aim to generate data on adherence to treatment guidelines, healthcare-seeking behaviour, magnitude of respiratory syncytial virus infection, antimicrobial resistance, PK/PD of commonly used antibiotics and generate novel recommendations for antibiotic treatments tailored to the populations in these diverse settings.

Topics

Who is involved

OrganisationCityCountryRole
University of Cape Town Lung Institute Pty Ltd*Cape TownSouth AfricaCoordinator
Armauer Hansen Research InstituteAddis AbabaETParticipant
The Registered Trustees of Lilongwe Medical Relief Fund TrustLilongweMWParticipant
Oxygen for Life InitiativeIbadanNGParticipant
Karolinska InstitutetStockholmSwedenParticipant
Uppsala UniversitetUppsalaSwedenParticipant
Farmovs (pty) LtdBloemfonteinSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI